

# Appendix 2

## Clinical review

### Data extraction form

<b>Study details</b>			
Endnote number		Ethnicity reported?	
First author		Language	
Year		Country	

<b>Eligibility checklist</b>	<b>Yes</b>	<b>No</b>	
Population >=18			If no, exclude
Population has mental illness			If yes, exclude
Population is overweight/obese or at high risk of CVD			If no, exclude
Treatment length >= 12 weeks			If no, exclude
Active intervention includes: orlistat 120mg with meals (maximum 360mg) sibutramine 10-15mg once daily rimonabant 20mg once daily			If no, exclude
Control group is lifestyle/exercise/placebo/standard care or metformin in T2DM/PCOS, or orlistat/sibutramine/rimonabant			If no, exclude
Control group is other active drug			If yes, exclude
Randomised			If no, exclude

Is the population included..... (please give percentages in boxes given)							
Diabetic	<input type="text"/>	Co morbidities	<input type="text"/>	Obese but healthy	<input type="text"/>	Mixed/other	<input type="text"/>
<b>Primary outcome</b>							
Type of RCT	Parallel	<input type="text"/>	Crossover	<input type="text"/>	Other - State		
No of arms	2	<input type="text"/>	3	<input type="text"/>	Other - State		
No of relevant arms	2	<input type="text"/>	3	<input type="text"/>	Other - State		
Treatment length (m)							
Time points (m)							
Weight:	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	
BMI:	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	T / G / GE / NR	
<b>Quality</b>							
Randomisation	None (0)	<input type="text"/>	Mentioned (1)	<input type="text"/>	Described and (2) adequate	<input type="text"/>	**If none – exclude**
Allocation concealment	None (0)	<input type="text"/>	Yes (1)	<input type="text"/>			

Double Blinding	None (0) <input type="checkbox"/>	Mentioned (1) <input type="checkbox"/>	Described and (2) adequate <input type="checkbox"/>	
Flow of participants	None (0) <input type="checkbox"/>	Described and (1) incomplete <input type="checkbox"/>	Described and (2) adequate <input type="checkbox"/>	Total score <input type="text"/>
Is QoL measured	Yes <input type="checkbox"/>	No <input type="checkbox"/>		
Is there a policy for continuation?	Yes <input type="checkbox"/>	No <input type="checkbox"/>		

For greater than two-arm trials use multiple sheets

### Arm 1 – Control Group

Placebo	Placebo + D	Standard care	Orlistat + D	Sibutramine + D	Rimonabant+ D
			Orlistat + E	Sibutramine + E	Rimonabant+ E
Orlistat	Sibutramine	Rimonabant	Orlistat + D&E	Sibutramine + D&E	Rimonabant + D&E
			Dietary	Exercise	

Dose:

Dietary detail:

Exercise detail:

### Arm 2 – Intervention group

Placebo	Placebo + D	Standard care	Orlistat + D	Sibutramine + D	Rimonabant+ D
			Orlistat + E	Sibutramine + E	Rimonabant+ E
Orlistat	Sibutramine	Rimonabant	Orlistat + D&E	Sibutramine + D&E	Rimonabant + D&E
			Dietary	Exercise	

Dose:

Dietary detail:

Exercise detail:

Was standard dietary advice given to all participants?  
standard?

Yes

No

above

Advice detail:

Was standard exercise advice given to all participants?  
standard?

Yes

No

above

Advice detail: